

Extension to Amoéba's portfolio of patents in Japan and Europe

Lyon, 27 July 2016 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating waterborne bacterial risk, announced today that it has obtained three new patents, two in Japan and one in Europe, as part of its objective to develop new applications for its biological biocide.

The patent "Method for the biological control of *Pseudomonas*" was granted in Japan by the Japanese Patents Office until 2032. Briefly, this patent confirms that AMOEBA's solution has biocidal action against the pathogenic bacteria *Pseudomonas*, primary germ responsible for nosocomial infections acquired in health-care institutions. It applies to the Domestic Hot Water (DHW) sector.

The patent "Method for the biological control of *Listeria*" was granted in Japan by the Japanese Patents Office and by the European Patents Office for the European zone. This patent is also valid until 2032. Briefly, this patent confirms that AMOEBA's solution has biocidal action against the pathogenic bacteria *Listeria*, which is frequently implicated in food-borne infections. It relates to water used to clean equipment and material which will come into contact with foodstuffs and animal feed.

"The two new patents granted in Japan will soon open extensive commercial perspectives for us in the world's 3rd largest economy. Japan has a dense and diverse industrial network covering numerous activity sectors; the country is brimming with opportunities for a growing company like AMOEBA, which offers a biological alternative to enterprises involved in the field of water treatment." declares **Fabrice Plasson, President of AMOEBA's Board of Directors**.



About AMOEBA: Based in Chassieu - France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7 bn⁽²⁾. AMOEBA is continuing with the regulatory procedures necessary to obtain provisional MA for all European countries for the "Air Cooled Towers" application. AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. For more information: www.amoeba-biocide.com.



(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets
(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

Contacts:

Amoéba
Christine GENDROT LAURAIN
Head of Communication
+33(0)6 6210 8370
christine.laurain@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial communication
+33(0)1 5688 1111
ggasparetto@actifin.fr